Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus

Atherosclerosis

Volumn 158, Issue 2, 2001, Pages 417-423

  Ichimaru, Naotsugu ^a,c   Takahara, Shiro ^a   Kokado, Yukito ^a   Wang, Jing Ding ^a   Hatori, Motoaki ^a   Kameoka, Hiroshi ^b   Inoue, Takashi ^b   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Inoue Hospital   (Japan)

^c Tel: +81 06 6879 3531 ^*  (Japan)

Author keywords

Cyclosporine; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia; Renal transplantation; Tacrolimus

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SIMVASTATIN; TACROLIMUS; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS; CHOLESTEROL; CYCLOSPORINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; LIPOPROTEINS; MALE; PROSPECTIVE STUDIES; SIMVASTATIN; TACROLIMUS;

EID: 0034808667     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00438-5     Document Type: Article

References (30)

1. Persistent hyperlipidemia in renal transplant patients
2. The prevalence of hyperlipidemia in renal transplant recipients
3. Ischemic heart disease: Major cause of death and graft loss after renal transplantation in Scandinavia
4. Cardiovascular disease after renal transplantation
5. Effect of hypertension, hyperlipidemia and cyclosporine A therapy on long-term renal allograft survival
6. Adverse effect of cyclosporin on serum cholesterol in renal transplant recipients
7. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia
8. Relation of cyclosporine blood levels to adverse effects on lipoproteins
9. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
10. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine
11. Effects of tacrolimus on hyperlipidemia after successful renal transplantation
12. Cyclosporine to tacrolimus: Effect on hypertension and lipid profiles in renal allografts
13. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
14. Cyclosporine A drug interactions, screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures if human hepatocytes and liver microsomes
15. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin
16. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
17. Plasma lipids following renal transplantation
18. Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients
19. Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients
20. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors
21. The familial hyperchylomicronaemia syndrome
22. HMG-CoA reductase inhibitor lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation
23. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine
24. Effects of fluvastatin on hyperlipidemia after renal transplantation: Influence of steroid therapy
25. Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B
26. Lovastatin decrease de novo cholesterol synthesis and LDL apo B-100 production rates in combined-hyperlipidemic males
27. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporine
28. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
29. Rhabdmyolysis and renal injury with lovastatin use
30. Rhabdmyolysis in-patients receiving lovastatin after cardiac transplantation